Pharmacology for Nurses · Drugs to Treat Parkinson’s Disease and Multiple Sclerosis
Anti-Parkinsonian Drugs
On this page 9 sections
In 30 seconds
No drug cures Parkinson’s disease (PD), but several classes meaningfully improve symptoms by restoring the brain’s dopamine–acetylcholine balance. Every anti-Parkinsonian drug works through one of four strategies: replace the missing dopamine, mimic it at receptors, slow its breakdown, or reduce opposing acetylcholine activity. The cornerstone is Levodopa Dopamine precursor that crosses into the brain and is converted to dopamine Full entry →, a dopamine precursor that crosses the blood–brain barrier and is converted into dopamine inside the brain; it is almost always combined with Carbidopa Stops levodopa being wasted outside the brain Full entry →, which blocks that conversion outside the brain. Other classes — dopamine agonists, MAO-B inhibitors, COMT inhibitors, anticholinergics, amantadine — fill different roles, often delaying or smoothing levodopa’s effects.
This is management, not a cure: choices, combinations, and timing are tailored to each person, and the disease keeps progressing underneath the therapy. Long-term levodopa use brings motor complications — Wearing-off Symptoms return before the next dose is due Full entry →, Dyskinesias Involuntary writhing movements, often at peak drug effect Full entry →, and unpredictable on–off fluctuations — problems nurses help people recognize and report. Because dosing decisions belong to prescribers, this guide covers classes and mechanisms only — verify specific drugs, doses, schedules, and monitoring against current references, the formulary, and prescriber orders.
Why this matters
For people with PD, medication timing is part of the treatment — doses are often scheduled around symptom control. Nurses teach people and families how to take these drugs as prescribed, recognize a good “on” versus a “wearing-off” period, and know what to report. Nurses also watch for adverse effects (nausea, confusion, orthostatic hypotension, impulse-control changes) and check interactions with the many other drugs older adults take. Getting this wrong — including stopping abruptly — can cause serious harm.
The college version
Core Concepts
Levodopa and carbidopa: the cornerstone
Levodopa is the most effective symptomatic drug for PD. Unlike dopamine, it crosses the blood–brain barrier; inside the brain, aromatic L-amino acid decarboxylase converts it to dopamine. The catch: that same enzyme converts levodopa outside the brain too, wasting it and causing nausea. Carbidopa is a decarboxylase inhibitor that does not cross the blood–brain barrier, so it blocks conversion only in the periphery. Combined, more levodopa reaches the brain with fewer peripheral side effects — hence the pair is always given together.
Dopamine agonists
Dopamine agonists (e.g., pramipexole, ropinirole, rotigotine; older ergot-derived bromocriptine) activate dopamine receptors directly, so they don’t depend on dying neurons. They are often used early in younger people to delay levodopa, or later as add-ons. They share levodopa-like side effects (nausea, orthostatic hypotension, sleepiness) plus a class-specific caution: some are associated with impulse-control disorders (compulsive gambling, shopping, eating, hypersexuality) that nurses should ask about directly.
MAO-B inhibitors
Monoamine oxidase type B (MAO-B) breaks down dopamine in the brain. MAO-B inhibitors (e.g., selegiline, rasagiline) block that breakdown, increasing the dopamine that remains. They can be used early for mild symptoms or added to smooth out wearing-off; because they affect monoamine metabolism, interaction cautions apply with serotonergic or sympathomimetic drugs — check current references.
COMT inhibitors
Catechol-O-methyltransferase (COMT) degrades levodopa, mostly in the periphery. COMT inhibitors (e.g., entacapone) are used with levodopa/carbidopa to extend each dose — they do not work alone, only protecting levodopa. Side effects include intensifying levodopa’s effects and discolored urine; one older agent (tolcapone) requires liver monitoring due to rare hepatotoxicity. Which agent and monitoring is a prescriber decision.
Anticholinergics
Anticholinergic Reduces acetylcholine activity Full entry → drugs (e.g., benztropine, trihexyphenidyl) reduce the relative acetylcholine excess in the striatum, rebalancing from the other side. They can help tremor, especially in younger people, but side effects — dry mouth, blurred vision, urinary retention, constipation, and confusion — limit their use, particularly in older adults. They are generally avoided or used cautiously in narrow-angle glaucoma, urinary obstruction, and dementia.
Amantadine
Amantadine is an NMDA (glutamate) receptor antagonist used mainly to reduce levodopa-induced dyskinesias, sometimes for mild early symptoms. Originally an antiviral — a reminder that drugs often have multiple mechanisms — its side effects include ankle edema and livedo reticularis (mottled skin).
Beyond drugs: DBS and the care team
Deep brain stimulation (DBS) — a surgically implanted electrode modulating basal ganglia circuits — is a non-drug option for selected people with motor fluctuations; candidacy is a specialized-team decision. Therapy, nutrition, fall prevention, and mental-health support round out the plan.
Nursing implications
- Timing is therapy: teach the exact schedule and how to report wearing-off or dyskinesias.
- Never stop abruptly: sudden withdrawal can cause severe rebound or a dangerous akinetic state; changes are prescriber-directed.
- Watch for orthostatic hypotension; teach slow position changes and monitor fall risk.
- Monitor cognition, especially in older adults.
- Check interactions — people with PD often take many drugs.
- Scope note: teaching, administration, and monitoring are nursing responsibilities; initiation and discontinuation follow prescriber orders and institutional policy.
Common Confusions
| Do not confuse | With | Difference |
|---|---|---|
| Levodopa | Carbidopa | Levodopa becomes dopamine in the brain; carbidopa only protects it from peripheral breakdown — useless alone |
| Dopamine agonists | Levodopa | Agonists mimic dopamine at receptors; levodopa must be converted and depends on remaining neurons |
| MAO-B inhibitors | COMT inhibitors | MAO-B protects dopamine in the brain; COMT protects levodopa in the periphery — different jobs |
| Dyskinesias (drug effect) | Parkinsonian tremor (disease) | Dyskinesias are peak-dose involuntary movements from the drug; tremor is a disease sign — both look like “shaking” but management differs |
“Drug holidays” are not recommended — changes are prescriber-directed | All MAO inhibitors | Each other | Interaction profiles differ by agent, selectivity, and dose |
Eli explains
The same idea, in plain words
Explain it like I’m 10
Parkinson’s disease happens when the brain runs low on a chemical called dopamine, which helps you move smoothly. The main medicine gives the brain the ingredients to make dopamine; a second stops them from being wasted in the rest of the body. Other medicines either pretend to be dopamine, make what’s left last longer, or turn down the brain’s “stop” signal — all so movement works better for longer. The medicines help, but the brain keeps changing, so doses and timing often need adjusting.
Worked example
A person with PD taking levodopa/carbidopa reports that “the medicine doesn’t last as long as it used to — by late afternoon my hand starts shaking and it’s hard to get out of the chair.” The nurse recognizes wearing-off: symptom control no longer lasts until the next dose. Rather than advising any dose change (a prescriber decision), the nurse documents the timing — last dose taken, when symptoms returned, how the person feels before and after doses — and reviews adherence: taken on time, with or without food? The nurse also asks about dizziness on standing, confusion, and any new compulsions. The observations are reported to the prescriber, who can adjust the regimen, timing, or add-on therapy based on the pattern.
Key takeaways
- Strategies: replace (levodopa), mimic (dopamine agonists), slow breakdown (MAO-B inhibitors), rebalance (anticholinergics, amantadine), protect levodopa (COMT inhibitors).
- Levodopa crosses the blood–brain barrier and is converted centrally; carbidopa blocks peripheral conversion, so the pair is given together.
- Long-term levodopa brings wearing-off, peak-dose dyskinesias, and on–off fluctuations — report rather than accept them as “the disease.”
- Dopamine agonists can cause impulse-control disorders; ask directly.
- Anticholinergics help tremor but are risky in older adults (confusion, urinary retention).
- Never discontinue anti-Parkinsonian drugs abruptly; withdrawal can be dangerous.
- COMT inhibitors only work alongside levodopa; they extend its effect.
- Verify all specifics against current references/formulary/prescriber orders — mechanism-level education only.
Check yourself
5 review questions from the chapter. Try each one, then open the answer.
Why is levodopa always combined with carbidopa?
Show answer
Carbidopa blocks the enzyme that converts levodopa to dopamine outside the brain, so more levodopa reaches the brain and peripheral side effects are reduced.
What are the four strategy families of anti-Parkinsonian drugs, and give one example class for each?
Show answer
Replace (levodopa), mimic (dopamine agonists), slow breakdown (MAO-B inhibitors), rebalance (anticholinergics, amantadine), with COMT inhibitors protecting levodopa.
What are wearing-off and peak-dose dyskinesias, and why do they develop with long-term levodopa?
Show answer
As neurons die, the brain can no longer store dopamine, so symptom control tracks drug levels: symptoms return before the next dose (wearing-off) and involuntary movements appear at peak effect (dyskinesias).
Which side effect of dopamine agonists should nurses ask about directly?
Show answer
Impulse-control disorders — compulsive gambling, shopping, eating, or hypersexuality.
Why must anti-Parkinsonian drugs never be stopped abruptly?
Show answer
Abrupt withdrawal can cause severe rebound or a dangerous akinetic state; any change must be directed by the prescriber.
Study tools & related lessonsKey vocabulary · Related
Key vocabulary
- Levodopa
- Dopamine precursor that crosses into the brain and is converted to dopamine
- Carbidopa
- Stops levodopa being wasted outside the brain
- Dopamine agonist
- Activates dopamine receptors directly
- MAO-B inhibitor
- Blocks dopamine breakdown in the brain
- COMT inhibitor
- Blocks an enzyme that degrades levodopa
- Anticholinergic
- Reduces acetylcholine activity
- Wearing-off
- Symptoms return before the next dose is due
- Dyskinesias
- Involuntary writhing movements, often at peak drug effect
- On–off phenomenon
- Unpredictable swings between good (“on”) and poor (“off”) control
- NMDA receptor antagonist
- Blocks a glutamate receptor (amantadine)
Sources & references
This lesson was adapted from the open educational references above; their licenses and attributions are preserved. See Copyright & Licensing.
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.